Refractory Acute Myeloid Leukemia
Phase 3 trial in advanced AML misses primary endpoint
A randomized phase 3 trial designed to evaluate the addition of enasidenib to best supportive care for certain patients with acute myeloid leukemia failed to meet its primary endpoint, according to the agent’s manufacturer.
Gemtuzumab ozogamicin plus venetoclax shows promise in relapsed, refractory AML
Researchers reported early evidence of anti-leukemic effect in a phase 1b study of combination gemtuzumab ozogamicin and venetoclax in relapsed or refractory acute myeloid leukemia patients in a presentation at the ASCO20 Virtual Scientific Program.
HSCT after quizartinib or chemotherapy extends OS in AML subset
ORLANDO — Hematopoietic stem cell transplantation after treatment with quizartinib or salvage chemotherapy extended survival among patients with FLT-internal tandem duplication-mutated relapsed or refractory acute myeloid leukemia, according to post-hoc analyses of the randomized QuANTUM-R study presented at TCT | Transplantation & Cellular Therapy Meetings.